| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Korean J Urol Oncol > Volume 13(1); 2015 > Article
The Korean Journal of Urological Oncology 2015;13(1): 29-34.
전립선비대증의 치료로 Tamsulosin, Finasteride 병합요법시 투여 방법 및 증상호전에 따른 약물 순응도의 차이 분석
김규식, 정재훈1, 김태효2, 이기수2, 이승욱
한양대학교 의과대학 비뇨기과학교실, 1속초 공중보건지소, 2동아대학교 의과대학 비뇨기과학교실
Symptom and Differences in Medication Adherence in Method of Administration of Tamsulosin, Finasteride Combination Therapy in Benign Prostatic Hyperplasia
Kyu Shik Kim , Jae Hoon Chung 1, Tae Hyo Kim 2, Ki Soo Lee 2, Seung Wook Lee
Department of Urology, College of Medicine, Hanyang University, Guri, 1Sok-cho General Health Care Center, Sokcho, 2Department of Urology, College of Medicine, Dong-A University, Busan, Korea
Published online: April 30, 2015.
ABSTRACT
Purpose:
It has been reported in several for factors on the drug compliance of patients, number of drug being taken, symptom, and pharmaceutical dosage form. However, Studies of drug compliance by dosing methodologies of tamsulosin, finasteride combination therapy and symptom relief for benign prostatic hyperplasia has not been performed. Therefore, we studied for symptom and differences in medication adherence in method of administration of tamsulosin, finasteride combination therapy.
Materials and Methods:
The groups were consisted in need of combination therapy of tamsulosin, finasteride on benign prostatic hyperplasia, one had packaged both drugs together (Group A, n=30) and the other were individually packaged both agents (Group B, n=30). International Prostatic Symptom Score (IPSS) were checked on first, 4weeks, and 8weeks. The evaluation was carried out of medicine compliance by checking the number of drugs 4weeks-interval. which was every 4weeks during 8weeks.
Results:
The properties other than the PSA in both groups, there was no statistically significant differences between patients. In first 4weeks, drug compliance of each Group A and B had tamsulosin 82.6%, 93.3% (p=0.033), finasteride 80.1%, 93.3% (p=0.042), and last 4weeks tamsulosin 80.6%, 93.7% (p=0.013), finasteride 79.5%, 93.7% (p=0.002) were checked. Group C, D had 81.4%, 96.4% (p=0.021) on 4weeks, 80.6%, 97.2% (p=0.011) on 8weeks.
Conclusions:
For co-administration of finasteride and tamsulosin are required in patients with benign prostatic hyperplasia, in order to enhance drug compliance, both tablets have to prescript together in one package to be taken at one time is useful. (Korean J Urol Oncol 2015;13:29-34)
Key Words: Prostatic hyperplasia; Compliance; Tamsulosin; Finasteride
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
385
View
26
Download
Related article
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 developed in m2community
Close layer
prev next